wiley | Following the severe acute respiratory syndrome coronavirus (SARS‐CoV)
and Middle East respiratory syndrome coronavirus (MERS‐CoV), another
highly pathogenic coronavirus named SARS‐CoV‐2 (previously known as
2019‐nCoV) emerged in December 2019 in Wuhan, China, and rapidly spreads
around the world. This virus shares highly homological sequence with
SARS‐CoV, and causes acute, highly lethal pneumonia (COVID‐19) with
clinical symptoms similar to those reported for SARS‐CoV and MERS‐CoV.
The most characteristic symptom of COVID‐19 patients is respiratory
distress, and most of the patients admitted to the intensive care could
not breathe spontaneously. Additionally, some COVID‐19 patients also
showed neurologic signs such as headache, nausea and vomiting.
Increasing evidence shows that coronavriruses are not always confined to
the respiratory tract and that they may also invade the central nervous
system inducing neurological diseases. The infection of SARS‐CoV has
been reported in the brains from both patients and experimental animals,
where the brainstem was heavily infected. Furthermore, some
coronaviruses have been demonstrated able to spread via a
synapse‐connected route to the medullary cardiorespiratory center from
the mechano‐ and chemoreceptors in the lung and lower respiratory
airways. In light of the high similarity between SARS‐CoV and SARS‐CoV2,
it is quite likely that the potential invasion of SARS‐CoV2 is
partially responsible for the acute respiratory failure of COVID‐19
patients. Awareness of this will have important guiding significance for
the prevention and treatment of the SARS‐CoV‐2‐induced respiratory
failure.
0 comments:
Post a Comment